Cellular Therapies and IDRx, crossed the $1 billion mark, a notable decrease from the six seen during the same period last ...
The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...
More than three-quarters of private biotech investment tracked by BioPharma Dive between January and March was distributed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback